By
AmyT on
November 4, 2008
Again, Januvia is one of the most searched-for terms on this site — which is interesting, because it’s an oral drug for controlling Type 2 diabetes with which I have no personal experience. But there’s a “perfect storm” surrounding Januvia that encapsulates many of the controversial themes running through diabetes care:
Show Me the Money
If you recall, Januvia is an oral DPP-4 inhibitor that lowers blood sugar by inhibiting glucagon release, versus the GLP-1…
Read more »
By
AmyT on
October 29, 2008
I met Alexis at the recent BDI luncheon for women with Type 1 diabetes. She seemed bubbly and smart, and I felt an instant connection. When I discovered her job title was “Compliance Analyst,” I just had to hear more about that. Turns out it’s not quite what you think, but fascinating nevertheless.
A Guest Post by Alexis Pollack —
Compliance Analyst, Amylin Pharmaceuticals, Inc.
Type 1 diabetes for 15 years
Compliance. It’s not a…
Read more »
I noticed a lot of chatter of late on diabetes forum sites about Symlin use. Some are still on the fence about trying this synthetic form of the human hormone Amylin, normally made by the beta cells, which helps level out post-meal glucose peaks. Others are just grateful that it’s now available in a convenient injection pen.
In early June, Amylin reported results of a study using Symlin with 112 patients with Type 2 diabetes,…
Read more »
By
AmyT on
February 26, 2008
Rumors will fly. They always do. Don’t ever think the world of health and medicine is any exception to that rule. Here are some details I’ve dug up on three that readers have run by me lately:
1) “On the CWD forums of late, a few people have been citing a failure rate of 20% for pods. Someone even said they were able to verify that with their Omnipod rep and that a manufacturing defect…
Read more »
Lots of buzz this week about Amylin, makers of Symlin and Byetta injectable blood-glucose stabilizers for Type 1 and Type 2 diabetics respectively.
Actually, the CNN Money correspondent covering Amylin spent a good deal of time sitting right next to me, but since peering over the shoulder of journalists as they’re typing is a faux pas at best, I don’t have the financial scoop. What I can tell you is that the word among conference…
Read more »
